Commercial code

Second convening of the Extraordinary Shareholder Meeting on March 8, 2023

Retrieved on: 
Thursday, February 16, 2023
Bulletin, CET, Patient, Proxy, Commercial code, Balo, Security (finance)

Second convening of the Extraordinary Shareholder Meeting on March 8, 2023

Key Points: 
  • Second convening of the Extraordinary Shareholder Meeting on March 8, 2023
    Paris, France, February 16, 2023 – 6.00 pm CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that its extraordinary shareholder meeting, convened a second call to vote on the same agenda as the extraordinary shareholder meeting of February 15, 2023.
  • The meeting will be held on Wednesday, March 8, 2023 at 10:30 a.m. at the Company's registered office.
  • The extraordinary shareholder meeting of the Company initially scheduled for February 15, 2023 could not deliberate as it did not obtain the legally required quorum.
  • The agenda and the text of the resolutions of the initial extraordinary shareholder meeting, that was scheduled on February 15, 2023, in the notice that was published in the BALO n°12 of January 27, 2023, remain unchanged.

Voting Rights and Shares Capital of the Company

Retrieved on: 
Tuesday, February 14, 2023
Nanobiotix, Commercial code, Security (finance), Property management

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

Key Points: 

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

Affluent Medical : Affluent Medical announces the launch of a capital increase of around €13 million with preferential subscription rights maintained by shareholders

Retrieved on: 
Monday, February 13, 2023
Ex-dividend date, Minerva, ISIN, Mitral insufficiency, Union, Dry, Aix-en-Provence, BSAR, Prospectus, Urinary incontinence, Person, Equity carve-out, Absar Alam (journalist), Exercise, Patient, Quality of life, Adrenal insufficiency, Voluntary Optimisation of Class Structure Scheme, Commercial code, Parity, Artus, DPS, Nightclub, Security (finance), Medical imaging, Medical device, Bank, Management, Euronext Paris, Bpifrance

Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "Affluent Medical enters 2023 with a clear roadmap and strong ambitions.

Key Points: 
  • Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "Affluent Medical enters 2023 with a clear roadmap and strong ambitions.
  • The development of accessories for Epygon and the industrialization of medical devices Epygon and Artus would be postponed.
  • Each shareholder of Affluent Medical may subscribe for 13 ABSARs on an irreducible basis for 28 existing shares held, i.e.
  • Preferential subscription rights will be traded on Euronext Paris from February 10, 2023 to February 23, 2023, inclusive, under ISIN code FR001400FL20.

Cellectis Announces Launch of Follow-On Offering

Retrieved on: 
Thursday, February 2, 2023
Telephone, EDGAR, Council, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Attention, Broadridge Financial Solutions, Security (finance), European Parliament, Jefferies Group, ADSS, Madison Avenue, ADS, Sale, European, American depositary receipt, UCART123, Commercial code, Euronext Growth, Form, Conseil, Prospectus, MAR, Cellectis, EU

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the launch of a global offering of USD 22 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”) pursuant to an underwriting agreement, to be entered into by Cellectis, Jefferies LLC and Barclays Capital Inc.

Key Points: 
  • NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the launch of a global offering of USD 22 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”) pursuant to an underwriting agreement, to be entered into by Cellectis, Jefferies LLC and Barclays Capital Inc.
  • Jefferies LLC and Barclays Capital Inc. (the “Underwriters”) are acting as joint book-running managers for the Global Offering.
  • The Global Offering is subject to market and other conditions and the final aggregate amount of the Global Offering is subject to change.
  • In particular, no public offering of the ADSs will be made in Europe.

Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents

Retrieved on: 
Friday, January 27, 2023
CET, Mass meeting, Bulletin, Extraordinary general meeting, Patient, Commercial code

The prior notice of the Extraordinary General Meeting containing the agenda and the draft resolutions presented by the Board of Directors for agreement by the shareholders was published in the BALO n°5 (Bulletin des Annonces Légales Obligatoires) on January 11, 2023 and the convening notice was published in the BALO n°12 on January 27, 2023 and in the Affiches Parisiennes (legal newspaper).

Key Points: 
  • The prior notice of the Extraordinary General Meeting containing the agenda and the draft resolutions presented by the Board of Directors for agreement by the shareholders was published in the BALO n°5 (Bulletin des Annonces Légales Obligatoires) on January 11, 2023 and the convening notice was published in the BALO n°12 on January 27, 2023 and in the Affiches Parisiennes (legal newspaper).
  • The information regarding the Extraordinary General Meeting mentioned in article R. 225-83 of the French Commercial Code can be found as of today on the Company’s website www.pixium-vision.com , under « Investors », « Shareholder’s General Meeting ».
  • The documents and information mentioned in articles R.225-81 and R.225-83 of the French Commercial Code can be sent to shareholders upon request to the Company.
  • Shareholders will also be able to consult the documents at the Company’s registered office located in Paris (75012), 74, rue du Faubourg Saint Antoine, during 15 days prior to the General Meeting.

EQS-News: ADVA Optical Networking SE: Domination and profit and loss transfer agreement between ADVA Optical Networking SE and ADTRAN Holdings, Inc., has been registered in the commercial register

Retrieved on: 
Thursday, February 2, 2023
ADVA Optical Networking, ADTN, Commercial code, FSE, Solidarity, Security (finance)

ADVA Optical Networking SE: Domination and profit and loss transfer agreement between ADVA Optical Networking SE and ADTRAN Holdings, Inc., has been registered in the commercial register

Key Points: 
  • ADVA Optical Networking SE: Domination and profit and loss transfer agreement between ADVA Optical Networking SE and ADTRAN Holdings, Inc., has been registered in the commercial register
    The issuer is solely responsible for the content of this announcement.
  • Domination and profit and loss transfer agreement between ADVA Optical Networking SE and ADTRAN Holdings, Inc., has been registered in the commercial register
    Munich, Germany.
  • The extraordinary general meeting of ADVA had granted approval to the conclusion of the DPLTA on November 30, 2022.
  • They are entitled to receive a fixed annually recurring compensation payment from ADTRAN Holdings for the duration of the DPLTA.

Voting Rights and Shares Capital of the Company

Retrieved on: 
Wednesday, January 11, 2023
Commercial code, Nanobiotix, Security (finance), Euronext

As a reminder, Nanobiotix has announced on December 21, 2022, that it has ended the liquidity contract signed on October 23, 2012, with Gilbert Dupont.

Key Points: 
  • As a reminder, Nanobiotix has announced on December 21, 2022, that it has ended the liquidity contract signed on October 23, 2012, with Gilbert Dupont.
  • The termination is effective from December 20, 2022, after the close of Euronext market.
  • According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

Nicox Announces Proposed Move to Euronext Growth Paris

Retrieved on: 
Monday, January 9, 2023
Transfer, Euronext Growth, AMF, Person, Council, Euronext Paris, Communication, Commercial code, European Parliament, Internet, European, Policy, Euronext, Risk management, CEST, COX, Proxy, Disclosure, MAR, D, Holding company, Airline, Security (finance), Audit, Medical device, EU

This ordinary shareholder meeting will decide on the proposed transfer of the listing of securities issued by the Company from the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading facility (the “Transfer”), and will be asked to grant the Board of Directors all the powers necessary to carry out this Transfer.

Key Points: 
  • This ordinary shareholder meeting will decide on the proposed transfer of the listing of securities issued by the Company from the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading facility (the “Transfer”), and will be asked to grant the Board of Directors all the powers necessary to carry out this Transfer.
  • Euronext Growth Paris is a market organized by Euronext Paris.
  • Any company listed on Euronext Growth Paris must ensure the effective and full dissemination of the so-called regulated information.
  • As Euronext Growth Paris is not a regulated market, the transfer to Euronext Growth Paris could result in a change in the liquidity of the shares which could differ from the liquidity observed since the beginning of the Company's listing on the Euronext Paris regulated market.

Linedata Services: Results of the public share buyback offer initiated by Linedata Services for its own shares

Retrieved on: 
Sunday, January 22, 2023
Human, Regulatory News Service, Share repurchase, Commercial code, Security (finance)

The Share Buyback Offer was open between December 2 and 22, 2022, inclusive, and offered to Company shareholders to buy back their Linedata Services shares for a maximum of 1,100,000 shares at a unit price of 50.00 euros (€50.00).

Key Points: 
  • The Share Buyback Offer was open between December 2 and 22, 2022, inclusive, and offered to Company shareholders to buy back their Linedata Services shares for a maximum of 1,100,000 shares at a unit price of 50.00 euros (€50.00).
  • The Company will buy back 1,100,000 of its own shares for an amount of €55,000,000.
  • the settlement-delivery of the Share Buyback Offer will take place on December 28, 2022;
    and the shares bought back as part of the Share Buyback Offer will be cancelled on December 28, 2022.
  • At the end of the share cancellation period, the capital of the Company will be reduced to €4,960,807, made up of 4,960,807 shares.

Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

Retrieved on: 
Monday, December 12, 2022
Finance, Mucopolysaccharidosis, IVA, Factor X, Pharmacology, Partnership, Food, Sale, Chronic liver disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MPS, NASH, Pharmacokinetics, European Investment Bank, ISIN, Fruit, Exercise, EIB, Commercial code, Fatty liver disease, Research, Computational chemistry, Sino Biopharmaceutical Limited, Biology, ATM, Patient, MPS VI, Pharmaceutical industry, Security (finance), Euronext Paris

Jean Volatier, Chief Financial Officer of Inventiva, stated: “We are pleased to see that our long-term partnership with the EIB is bearing fruit.

Key Points: 
  • Jean Volatier, Chief Financial Officer of Inventiva, stated: “We are pleased to see that our long-term partnership with the EIB is bearing fruit.
  • Any drawings under the terms of the Finance Contract that have not been disbursed within 36 months from the signing of the Finance Contract, (i.e., before May 16, 2025), cannot be completed at a later date.
  • On November 4, 2022, the Company received an upfront payment of $12 million under its collaboration agreement with Sino Biopharm.
  • on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract.